Biography
Charles Raison, MD, is the Mary Sue and Mike Shannon Chair for Healthy Minds, Children & Families and Professor, School of Human Ecology, and Professor, Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison in
Madison, WI. Dr. Raison also serves as Director of Clinical and Translational Research for Usona Institute and as Director of Research on Spiritual Health for Emory Healthcare in Atlanta, GA. In addition, Dr. Raison has served as a mental health expert for CNN.com for many years. Dr. Raison is internationally recognized for his studies examining novel mechanisms involved in the development and treatment of major depression and other stress-related emotional and physical conditions, as well as for his work examining the physical and behavioural effects of compassion training. More recently, Dr. Raison has taken a leadership role in the development of psychedelic medicines as potential treatments for major depression. The recipient of several teaching awards, Dr. Raison has received research funding from the National Institute of Mental Health, National Centre for Complementary and Alternative Medicine, and the Centres for Disease Control and Prevention.
Abstract
The psychedelic medicine industry surges with investments in start-ups promising to address the lack of effective mental health treatments. The greatest challenge facing development of psychedelics as medicines will not be what to do when they don’t work but when they do work. I will draw upon specific case studies, clinical research, and current psychotherapy models to prompt the audience to consider key questions, challenges, and opportunities that need to be addressed such as dosing strategies, long-term vs. short-term efficacy in relation to clinical diagnoses, and therapeutic support systems to optimise treatment. I will also touch on the latest developments with our work at the Usona Institute running trials for psilocybin in treatment of Major Depressive Disorder.
Other Speakers at ICPR 2022
Founder and Executive Director at MAPS, the Multidisciplinary Association for Psychedelic Studies, United States
Associate Professor at Faculty of Psychology and Neuroscience at Maastricht University, The Netherlands
Ready To Attend ICPR 2022?
Join the leading conference in Europe dedicated to advancing psychedelic research and therapies.
About ICPR
The Interdisciplinary Conference on Psychedelic Research (ICPR) is Europe’s leading academic conference dedicated to advancing psychedelic research and therapies organised by the OPEN Foundation since 2010. ICPR is a biennial conference focused on high-quality scientific and scholarly research into psychedelics. ICPR 2022 is our fifth event. After our hugely successful online conference in 2020, we are returning to the prestigious Philharmonie Theatre for an in-person event! ICPR will take place in Haarlem (next to Amsterdam) from September 22nd to 24th, 2022.
